A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers

James L. LaBelle, Samuel G. Katz, Gregory H. Bird, Evripidis Gavathiotis, Michelle L. Stewart, Chelsea Lawrence, Jill K. Fisher, Marina Godes, Kenneth Pitter, Andrew L. Kung, Loren D. Walensky

Research output: Contribution to journalArticle

120 Citations (Scopus)

Abstract

Cancer cells subvert the natural balance between cellular life and death, achieving immortality through pathologic enforcement of survival pathways and blockade of cell death mechanisms. Pro-apoptotic BCL-2 family proteins are frequently disarmed in relapsed and refractory cancer through genetic deletion or interaction-based neutralization by overexpressed antiapoptotic proteins, resulting in resistance to chemotherapy and radiation treatments. New pharmacologic strategies are urgently needed to overcome these formidable apoptotic blockades. We harnessed the natural killing activity of BCL-2-interacting mediator of cell death (BIM), which contains one of the most potent BH3 death domains of the BCL-2 protein family, to restore BH3-dependent cell death in resistant hematologic cancers. A hydrocarbon-stapled peptide modeled after the BIM BH3 helix broadly targeted BCL-2 family proteins with high affinity, blocked inhibitory antiapoptotic interactions, directly triggered proapoptotic activity, and induced dose-responsive and BH3 sequence-specific cell death of hematologic cancer cells. The therapeutic potential of stapled BIM BH3 was highlighted by the selective activation of cell death in the aberrant lymphoid infiltrates of mice reconstituted with BIM-deficient bone marrow and in a human AML xenograft model. Thus, we found that broad and multimodal targeting of the BCL-2 family pathway can overcome pathologic barriers to cell death.

Original languageEnglish (US)
Pages (from-to)2018-2031
Number of pages14
JournalJournal of Clinical Investigation
Volume122
Issue number6
DOIs
StatePublished - Jun 1 2012
Externally publishedYes

Fingerprint

Cell Death
Peptides
Neoplasms
Proteins
Hydrocarbons
Heterografts
Bone Marrow
Radiation
Drug Therapy
Survival
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

LaBelle, J. L., Katz, S. G., Bird, G. H., Gavathiotis, E., Stewart, M. L., Lawrence, C., ... Walensky, L. D. (2012). A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers. Journal of Clinical Investigation, 122(6), 2018-2031. https://doi.org/10.1172/JCI46231

A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers. / LaBelle, James L.; Katz, Samuel G.; Bird, Gregory H.; Gavathiotis, Evripidis; Stewart, Michelle L.; Lawrence, Chelsea; Fisher, Jill K.; Godes, Marina; Pitter, Kenneth; Kung, Andrew L.; Walensky, Loren D.

In: Journal of Clinical Investigation, Vol. 122, No. 6, 01.06.2012, p. 2018-2031.

Research output: Contribution to journalArticle

LaBelle, JL, Katz, SG, Bird, GH, Gavathiotis, E, Stewart, ML, Lawrence, C, Fisher, JK, Godes, M, Pitter, K, Kung, AL & Walensky, LD 2012, 'A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers', Journal of Clinical Investigation, vol. 122, no. 6, pp. 2018-2031. https://doi.org/10.1172/JCI46231
LaBelle, James L. ; Katz, Samuel G. ; Bird, Gregory H. ; Gavathiotis, Evripidis ; Stewart, Michelle L. ; Lawrence, Chelsea ; Fisher, Jill K. ; Godes, Marina ; Pitter, Kenneth ; Kung, Andrew L. ; Walensky, Loren D. / A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers. In: Journal of Clinical Investigation. 2012 ; Vol. 122, No. 6. pp. 2018-2031.
@article{2e3bff81134c42da83ade145f57dc50f,
title = "A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers",
abstract = "Cancer cells subvert the natural balance between cellular life and death, achieving immortality through pathologic enforcement of survival pathways and blockade of cell death mechanisms. Pro-apoptotic BCL-2 family proteins are frequently disarmed in relapsed and refractory cancer through genetic deletion or interaction-based neutralization by overexpressed antiapoptotic proteins, resulting in resistance to chemotherapy and radiation treatments. New pharmacologic strategies are urgently needed to overcome these formidable apoptotic blockades. We harnessed the natural killing activity of BCL-2-interacting mediator of cell death (BIM), which contains one of the most potent BH3 death domains of the BCL-2 protein family, to restore BH3-dependent cell death in resistant hematologic cancers. A hydrocarbon-stapled peptide modeled after the BIM BH3 helix broadly targeted BCL-2 family proteins with high affinity, blocked inhibitory antiapoptotic interactions, directly triggered proapoptotic activity, and induced dose-responsive and BH3 sequence-specific cell death of hematologic cancer cells. The therapeutic potential of stapled BIM BH3 was highlighted by the selective activation of cell death in the aberrant lymphoid infiltrates of mice reconstituted with BIM-deficient bone marrow and in a human AML xenograft model. Thus, we found that broad and multimodal targeting of the BCL-2 family pathway can overcome pathologic barriers to cell death.",
author = "LaBelle, {James L.} and Katz, {Samuel G.} and Bird, {Gregory H.} and Evripidis Gavathiotis and Stewart, {Michelle L.} and Chelsea Lawrence and Fisher, {Jill K.} and Marina Godes and Kenneth Pitter and Kung, {Andrew L.} and Walensky, {Loren D.}",
year = "2012",
month = "6",
day = "1",
doi = "10.1172/JCI46231",
language = "English (US)",
volume = "122",
pages = "2018--2031",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "6",

}

TY - JOUR

T1 - A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers

AU - LaBelle, James L.

AU - Katz, Samuel G.

AU - Bird, Gregory H.

AU - Gavathiotis, Evripidis

AU - Stewart, Michelle L.

AU - Lawrence, Chelsea

AU - Fisher, Jill K.

AU - Godes, Marina

AU - Pitter, Kenneth

AU - Kung, Andrew L.

AU - Walensky, Loren D.

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Cancer cells subvert the natural balance between cellular life and death, achieving immortality through pathologic enforcement of survival pathways and blockade of cell death mechanisms. Pro-apoptotic BCL-2 family proteins are frequently disarmed in relapsed and refractory cancer through genetic deletion or interaction-based neutralization by overexpressed antiapoptotic proteins, resulting in resistance to chemotherapy and radiation treatments. New pharmacologic strategies are urgently needed to overcome these formidable apoptotic blockades. We harnessed the natural killing activity of BCL-2-interacting mediator of cell death (BIM), which contains one of the most potent BH3 death domains of the BCL-2 protein family, to restore BH3-dependent cell death in resistant hematologic cancers. A hydrocarbon-stapled peptide modeled after the BIM BH3 helix broadly targeted BCL-2 family proteins with high affinity, blocked inhibitory antiapoptotic interactions, directly triggered proapoptotic activity, and induced dose-responsive and BH3 sequence-specific cell death of hematologic cancer cells. The therapeutic potential of stapled BIM BH3 was highlighted by the selective activation of cell death in the aberrant lymphoid infiltrates of mice reconstituted with BIM-deficient bone marrow and in a human AML xenograft model. Thus, we found that broad and multimodal targeting of the BCL-2 family pathway can overcome pathologic barriers to cell death.

AB - Cancer cells subvert the natural balance between cellular life and death, achieving immortality through pathologic enforcement of survival pathways and blockade of cell death mechanisms. Pro-apoptotic BCL-2 family proteins are frequently disarmed in relapsed and refractory cancer through genetic deletion or interaction-based neutralization by overexpressed antiapoptotic proteins, resulting in resistance to chemotherapy and radiation treatments. New pharmacologic strategies are urgently needed to overcome these formidable apoptotic blockades. We harnessed the natural killing activity of BCL-2-interacting mediator of cell death (BIM), which contains one of the most potent BH3 death domains of the BCL-2 protein family, to restore BH3-dependent cell death in resistant hematologic cancers. A hydrocarbon-stapled peptide modeled after the BIM BH3 helix broadly targeted BCL-2 family proteins with high affinity, blocked inhibitory antiapoptotic interactions, directly triggered proapoptotic activity, and induced dose-responsive and BH3 sequence-specific cell death of hematologic cancer cells. The therapeutic potential of stapled BIM BH3 was highlighted by the selective activation of cell death in the aberrant lymphoid infiltrates of mice reconstituted with BIM-deficient bone marrow and in a human AML xenograft model. Thus, we found that broad and multimodal targeting of the BCL-2 family pathway can overcome pathologic barriers to cell death.

UR - http://www.scopus.com/inward/record.url?scp=84861834043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861834043&partnerID=8YFLogxK

U2 - 10.1172/JCI46231

DO - 10.1172/JCI46231

M3 - Article

C2 - 22622039

AN - SCOPUS:84861834043

VL - 122

SP - 2018

EP - 2031

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 6

ER -